Navigation Links
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
Date:5/11/2009

laborations with major pharmaceutical companies like Pfizer to co-develop PF-04523655 in DME, wet-AMD, and other potential ocular indications provides further credibility to our siRNA technology capabilities."

Jayakrishna Ambati M.D., Professor and Vice Chair, Department of Ophthalmology & Visual Sciences, University of Kentucky, member of Quark's Medical Advisory Board, and one of the authors on the study, stated, "My laboratory's research has shown that many siRNAs suppress neovascularization regardless of their sequences or targets and can have dangerous off target effects. For that reason, I'm gratified to see this research, suggesting that Quark is seeing success in developing siRNA compounds that are effective."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-04523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-04523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licens
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
4. Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 The Oklahoma tornado left ... ravage, the mayor of Moore, one of the heavily damaged ... a report from cnn.com. Reaching out to also be of ... and Safe Shield to counter the looming mold problem. , ... May 22, 2013, caused 24 deaths, My Cleaning Products shared. ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... January 6 Biopharmaceutical Company Kiadis,Pharma focused on ... field of bone marrow transplantation, announces today the ... (CMO). Dr. Egeler is a global,leading pediatric bone ... hemato-oncology. He brings,to Kiadis Pharma over more than ...
... Pa., Jan. 5 West Pharmaceutical Services, Inc. (NYSE: WST ... , CJS ... York City. The presentation is scheduled for 1:55pm on Wednesday, January 7, ... , Sidoti & ...
... Nektar Therapeutics,(Nasdaq: NKTR ) President and Chief ... the upcoming 27th Annual J.P. Morgan Healthcare,Conference in San ... 13, 2009 at 10:00 a.m. Pacific time (1:00 p.m. ... will be accessible via a Webcast through a link ...
Cached Biology Technology:Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 2West to Present at Upcoming Conferences 2
(Date:5/24/2013)... and destruction by the immune system. Stimulation of the ... there are many factors that cause the immune system ... cells that function to suppress the immune system response. ... Investigation , researchers led by Ronald Levy at Stanford ... express proteins that can be targeted with therapeutic antibodies. ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... More than one in four elderly patients was given ... of a study by Ute Amann and her co-authors ... International ( Dtsch Arztebl Int 2012; 109[5]: ... can increase the risk of undesired drug effects, and ...
... of cardiovascular pathologies seem to have a higher cancer ... published in detail in the Archives of Internal ... supplementation with B vitamins has some benefits for protecting ... in recent years remain equivocal., The results of studies ...
... Hugh Ducklow, senior scientist and director of the ... to the U.S. Antarctic Program Blue Ribbon Panel. ... Holdren, director of the White House Office of Science ... National Science Foundation, is tasked with examining the status ...
Cached Biology News:Vitamin B and omega-3 supplementation and cancer: New data 2MBL's Hugh Ducklow appointed to Antarctic Blue Ribbon Panel 2
... with a molecular weight of 16 kDa. Leptin ... produced by adipocytes [1,2]. Leptin is thought to ... weight [1-3]. In the human, leptin levels are ... [4]. A relationship between serum leptin levels and ...
... We can introduce random mutations to the ... be then cloned into a vector of choice ... Mutation frequency can be set to a ... Number of clones 106-108. Mutations can be ...
Request Info...
... plasmid DNA preparations are prepared from ... from 1mg to multi-gram scales. Each ... needs, and glycerol stocks are maintained ... clonal selection (Clonal selection includes screening ...
Biology Products: